MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...

Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...

The FDA has approved durvalumab (Imfinzi) plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for the treatment ...

Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...

Benjamin George, MD, has significantly improved cancer care access in rural Nebraska, Colorado, and Kansas, transforming ...

While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...

The IGNYTE trial reveals that RP1 combined with nivolumab offers significant, durable responses in advanced melanoma patients ...

The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and ...

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.

A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...